Kristi Rosa

New study findings suggest that more at-risk individuals should take pre-exposure prophylaxis to prevent HIV.

Eravacycline is an investigational drug candidate for the treatment of complicated intra-abdominal infections.

Tetraphase Pharmaceuticals today announced submission of its new drug application (NDA) to the FDA for eravacycline, in IV form, for the treatment of complicated intra-abdominal infections (cIAI).

Janssen submits new drug application for darunavir-based, once-daily, single-tablet regimen for the treatment of HIV in adults and adolescents who are 12 years of age or older.